Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights (GlobeNewswire) - Apr 30, 2025 - "The American College of Rheumatology's (ACR) newly updated treatment guidelines for lupus nephritis (LN) have led specialists to reconsider their treatment approaches, particularly around the use of triple therapy and the potential future role of Roche/Genentech's Gazyva (obinutuzumab), which is expected to receive FDA approval for LN later this year.... The ACR conditionally recommends triple therapy—including glucocorticoids, mycophenolate mofetil (MMF) or cyclophosphamide, and either Benlysta or a calcineurin inhibitor (CNI)—for patients who are newly diagnosed, flaring, or have active Class III or IV ± V disease. For patients presenting with high levels of proteinuria (≥3 g/g), the ACR recommends triple therapy that includes a CNI, such as Lupkynis....The guidelines also address patients with pure Class V disease, recommending first-line triple therapy that includes a CNI rather than Benlysta in patients with proteinuria ≥1 g/g."
Clinical guideline • Lupus Nephritis
|